Evidence map›Paper›PMID 25888391›Full record

ArticleBMC infectious diseases2015

Multidrug resistant Vibrio cholerae O1 from clinical and environmental samples in Kathmandu city.

Upendra Thapa Shrestha, Nabaraj Adhikari, Rojina Maharjan, Megha R Banjara, Komal R Rijal, Shital R Basnyat, Vishwanath P Agrawal

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. NQR as a target for new antibiotics.Frontiers in microbiology · 2025
    Review
  5. Role of phage therapy in acute gastroenteritis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Review
  6. Antibiotics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Review
  9. Clinical and socio-environmental determinants of multidrug-resistant vibrio cholerae 01 in older children and adults in Bangladesh.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
  10. Article
  11. Characterisation ofThe Pan African medical journal · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Integrative and Conjugative Elements-PositiveFrontiers in microbiology · 2019
    Article
  16. Article
  17. Article
  18. Emergency response in water, sanitation and hygiene to control cholera in post-earthquake Nepal in 2016.Journal of water, sanitation, and hygiene for development : a journal of the International Water Association · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Upendra Thapa ShresthaResearch Laboratory for Biotechnology and Biochemistry (RLABB), Sanepa, Lalitpur, Nepal. upendrats@gmail.com.
Nabaraj AdhikariDepartment of Microbiology, Kantipur College of Medical Science (KCMS), Sitapaila, KTM, Nepal. adhinarinaba2004@yahoo.com.
Rojina MaharjanDepartment of Microbiology, Kantipur College of Medical Science (KCMS), Sitapaila, KTM, Nepal. maharjan.rojina@gmail.com.
Megha R BanjaraCentral Department of Microbiology, Tribhuvan University, Kirtipur, KTM, Nepal. banjaramr@gmail.com.
Komal R RijalCentral Department of Microbiology, Tribhuvan University, Kirtipur, KTM, Nepal. rijalkomal@gmail.com.
Shital R BasnyatDepartment of Microbiology, Kantipur College of Medical Science (KCMS), Sitapaila, KTM, Nepal. basnyatshitalraj@yahoo.com.
Vishwanath P AgrawalResearch Laboratory for Biotechnology and Biochemistry (RLABB), Sanepa, Lalitpur, Nepal. vpa@wlink.com.np.
Tribhuvan University · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCholera, an infectious disease caused by Vibrio cholerae, is a major public health problem and is a particularly burden in developing countries including Nepal. Although the recent worldwide outbreaks of cholera have been due to V. cholerae El Tor, the classical biotypes are still predominant in Nepal. Serogroup O1 of the V. cholerae classical biotype was the primary cause of a cholera outbreak in Kathmandu in 2012. Thus, this study was designed to know serotypes and biotypes of V. cholerae strains causing recent outbreak with reference to drug resistant patterns. Moreover, we also report the toxigenic strains of V. cholerae from both environmental and clinical specimens by detecting the ctx gene.

methodsTwenty four V. cholerae (n = 22 from stool samples and n = 2 from water samples) isolated in this study were subjected to Serotyping and biotyping following the standard protocols as described previously. All of the isolates were tested for antimicrobial susceptibility patterns using the modified Kirby-Bauer disk diffusion method as recommended by CLSI guidelines. The screening of the ctx genes (ctxA2-B gene) were performed by PCR method using a pair of primers; C2F (5'-AGGTGTAAAATTCCTTGACGA-3') and C2R (5'-TCCTCAGGGTATCCTTCATC-3') to identify the toxigenic strains of V. cholerae.

resultsAmong twenty four V. cholerae isolates, 91.7% were clinical and 8.3% were from water samples. Higher rate of V. cholerae infection was found among adults of aged group 20-30 years. All isolates were serogroups O1 of the V. cholerae classical biotype and sub serotype, Ogawa. All isolates were resistant to ampicillin, nalidixic acid and cotrimoxazole. 90.9% were resistant to erythromycin however, tetracycline was found to be the most effective drug for the isolates. All isolates were multidrug resistant (MDR) and possessed a ctx gene of approximately 400 base pairs indicating the toxigenic strains.

conclusionHundred percent strains of V. cholerae were MDR possessing a ctx gene. It suggests that toxigenic strains be identified and proper antibiotic susceptibility testing be conducted. This will allow effective empirical therapy to be used to treat and control cholera.

Indexed as

Drug Resistance, Multiple, BacterialSerotypingAdultAnti-Bacterial AgentsCholeraCholera ToxinCitiesCross InfectionDisease OutbreaksEnvironmentFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedNepalAnti-Bacterial AgentsCholera Toxin

Identifiers

PMID25888391
PMCPMC4350293
OpenAlexW1974086799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.